Pharmacological Therapy in Osteoarthritis

Yeong Wook Song

doi:10.5124/jkma.2003.46.11.958

J Korean Med Assoc > Volume 46(11); 2003 > Article

Song: Pharmacological Therapy in Osteoarthritis

Special Issue I

Arthritis

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2003; 46(11): 958-964.

Published online: November 30, 2003

DOI: http://dx.doi.org/10.5124/jkma.2003.46.11.958

Pharmacological Therapy in Osteoarthritis

Yeong Wook Song, M.D.

Department of Internal Medicine, Seoul National University College of Medicine & Hospital, Korea. ysong@snu.ac.kr

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Osteoarthritis (OA) is a common, chronic, and painful disorder characterized by cartilage loss. It is the most common among all rheumatic disorders and is a major cause of disability. OA can be managed with a variety of pharmacological therapies, including acetaminophen, traditional nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, and capsaicin. In this review, I describe the clinical efficacy and side effects of these pharmaceuticals and review disease-modifying osteoarthritis drugs (DMOAD), such as glucosamine, diacerein, and avocado/soybean unsaponifiables, of which the clinical efficacy still remains to be determined.

Osteoarthritis; Acetaminophen; Nonsteroidal anti-inflammatory drug; Disease modifying osteoarthritis drug

References

1. American College of Rheumatology subcommittee on osteoarthritis guidelines. [Special Articles] Recommendation for the medical management of osteoarthritis of the hip and knee : 2000 update. Arthirtis Rheum 2000;43:1905-1915.

2. NIH Conference. Osteoarthritis : New Insights, part I : The disease and its risk factors. Ann Intern Med 2000;133:635-646.

3. Sowers MF. Epidemiology of risk factors for osteoarthritis : systemic factors. Curr Opin Rheummatol 2001;13:447-451.

4. Sharma L. Local factors in osteoarthritis. Curr Opin Rheummatol 2001;13:441-446.

5. Doherty M. Risk factors for progression of knee osteoarthritis. Lancet 2001;358:775-776.

6. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41(8):1343-1355.

7. Jacobsson , Lennart TH. The epidemiology of osteoarthritis in the peripheral joints : definitions of osteoarthritis in the knee and hand. Ann Rheum Dis 1996;55(9):656-658.

8. Schouten Jan SAG, de Bie RA, Swaen G. An update on the relationship between occupational factors and osteoarthritis of the hip and knee. Curr Opin Rheummatol 2002;14:89-92.

9. Pelletier JP, Johanne MP, Abramson SB. Osteoarthritis, an inflammatory disease. Potential complication for the selection of new therapeutic targets. Arthritis Rheum 2001;41(6):1237-1247.

10. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43(9):1905-1915.

11. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al. NIH conference, New insights, Part 2 : Treatment approaches. Ann Intern Med 2000;133:726-737.

12. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et al. EULAR recommendations for the management of knee osteoarthritis : report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2000;59:936-944.

13. Jubb RW. Oral and intra-articular remedies : Review of papers published from March 2001 to February 2002. Curr Opin Rheummatol 2002;14:597-602.

14. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.

15. Maxime D, Minh N, Laurent B, Bernard M, Eric V, Michel L. Evaluation of the structure-modifying effects of diacerein in hip osteoarthiritis : ECHODIAH, a three-year, placebo-controlled trial. Arthirtis Rheum 2001;44:2539-2547.

16. Forent R, Oliver B, Olivier E, Michel C, Yves H, Jean-Yves R. Structural and symptomatic efficacy of glucosamine and chodroitin in knee osteoarthritis : A comprehensive meta-analysis. Arch Intern Med 2003;163:1514-1522.

17. Michel L, Emmanuel M, Christian C, Renée-Liliane D. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care Res 2003;47(1):50-58.

Pharmacological Therapy in Osteoarthritis

Abstract

References

Figure 1